Artivion
Open
$21.44
Prev. Close
$21.41
High
$21.48
Low
$21.37
Market Snapshot
$1.03B
87.9
-0.31
$388.54M
Artivion, Inc. engages in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The company is headquartered in Kennesaw, Georgia and currently employs 1,800 full-time employees. The firm operates through two segments, which include Medical Devices and Preservation Services. The medical devices and preservation services are primarily used by cardiac and vascular surgeons to treat patients with aortic disease, including heart valve disease, aortic aneurysms, and dissections, and, to a lesser extent, other conditions in cardiac and vascular surgery. The company has four product families: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. Its aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Its surgical sealants include BioGlue Surgical Adhesive products.
Artivion, Inc. engages in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The company is headquartered in Kennesaw, Georgia and currently employs 1,800 full-time employees. The firm operates through two segments, which include Medical Devices and Preservation Services. The medical devices and preservation services are primarily used by cardiac and vascular surgeons to treat patients with aortic disease, including heart valve disease, aortic aneurysms, and dissections, and, to a lesser extent, other conditions in cardiac and vascular surgery. The company has four product families: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. Its aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Its surgical sealants include BioGlue Surgical Adhesive products.
Recently from Cashu

Artivion Reports Revenue Growth Amid Concerns Over Earnings and Profitability Challenges
Artivion (Ticker: AORT) addresses a critical juncture in its growth narrative against the backdrop of its latest financial report. Revenue Growth Amid Profitability Concerns The company experiences a…
Artivion Reports Revenue Growth Amid Challenges and Investigations in Financial Performance
Artivion, Inc. (Ticker: AORT) has reported significant achievements alongside notable challenges following its latest financial disclosures. In the first quarter of 2026, the company showcases a reven…

Artivion Gains FDA Approval for NEXUS Aortic Arch System, Eyes Acquisition of Endospan
In a significant advancement within the cardiovascular device sector, Artivion, Inc. receives FDA approval for the Premarket Approval (PMA) of the NEXUS Aortic Arch System, developed by Endospan. This…

Artivion's NEXUS Approval Boosts Growth Potential in Aortic Disease Treatment Market
Artivion makes significant strides in aortic disease treatment with the FDA's recent approval of its NEXUS Aortic Arch System. This innovative technology is pivotal for patients suffering from aortic…